2 enrolling by invitation. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Enrolling by invitation 2 |
| Phase 2 | 1 | Enrolling by invitation 1 |
Follow Hereditary Angioedema: new trials by email Literature Review of Hereditary Angioedema trials Research Report on Hereditary Angioedema
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema deucrictibant - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 2 / Phase 3 | Enrolling by invitation | Pharvaris Netherlands B.V. | 150 | 2022-12-28 | 2026-07-21 |
| Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies berotralstat - Hereditary Angioedema, HAE | Phase 3 | Enrolling by invitation | BioCryst Pharmaceuticals | 139 | 2021-07-23 | 2025-12-23 |
Angioedemas, Hereditary (2) · Hereditary Angioedema Type III (1) · Hereditary Angioedema Types I and II (1)
Angioedema (2) · Cardiovascular Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Hereditary Complement Deficiency Diseases (2) · Hypersensitivity (2) · Hypersensitivity, Immediate (2) · Immune System Diseases (2) · Immunologic Deficiency Syndromes (2) · Primary Immunodeficiency Diseases (2) · Skin Diseases (2) · Skin Diseases, Vascular (2) · Skin and Connective Tissue Diseases (2) · Urticaria (2) · Vascular Diseases (2)
berotralstat (1)
BioCryst Pharmaceuticals (1) · Pharvaris Netherlands B.V. (1)
Canada (2) · Czechia (2) · France (2) · Germany (2) · Poland (2) · South Africa (2) · South Korea (2) · Spain (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Austria (1) · Brazil (1) · Bulgaria (1) · Hong Kong (1)
Vesna Grivcheva-Panoska, MD, PhD (1)
2023 (1)